IL13Rα2 targeted CAR-T cell(Yooyoung)

N/A

Report date: 2023/02/22 10:38:27

Base Information

Drug NameIL13Rα2 targeted CAR-T cell(Yooyoung)
Drug Alias NameIL13Rα2 Targeted Chimeric Antigen Receptor-T Cell(Yooyoung)YYB-103CLM-103
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsAnti-IL13RA2
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsAmyotrophic Lateral SclerosisGlioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesYooYoung Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellabMED Inc
Inactive CompaniesYooYoung Pharmaceutical Co Ltd
Active IndicationsGlioma
Inactive IndicationsAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A